Jun 23, 2025 at 3:18 AM#2
cory_ATX, these results are textbook GLP-1 benefit in MASLD/MASH. Let me put some context around your numbers for others reading:
ALT is the most liver-specific aminotransferase. Your drop from 94 to 22 represents resolution of active hepatocellular injury. A normal ALT doesn't guarantee zero steatosis, but it strongly suggests reduced inflammation.
GGT is often the most sensitive marker for fatty liver. Going from 118 to 28 is remarkable — that's a 76% reduction.
FIB-4 combines age, AST, ALT, and platelets into a fibrosis risk score. Your improvement from 2.14 to 0.78 correlates with likely fibrosis regression. The SYNERGY-NASH trial with tirzepatide showed MASH resolution in 74% and fibrosis improvement in 47% of patients at 15mg — you're tracking right in line with trial data.
Rising platelets (158 to 198) is also a good sign — low platelets can indicate portal hypertension from liver fibrosis, and your improvement suggests reduced hepatic pressure.
Keep doing what you're doing. The FibroScan in December will give you more definitive staging.
49 19laura_annarbor, JenMemphis, pat_auckland and 46 others
Reply Quote Save Share Report